Brind.

Erasca, a company focused on therapies for RAS-driven cancers, received FDA clearance for its IND applications.

3 reports, 1 independent Updated Sep 4

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Erasca, a company focused on therapies for RAS-driven cancers, received FDA clearance for its IND applications.

Who's involved

What this event is mainly about

Erasca (United States)FDA

Keep exploring

The entities involved

Erasca (United States)
company in San Diego, United States

Nothing else this week.
FDA
- FDA data is being utilized by Idan Hecht's team, who are affiliated with Mayo Clinic.19:39
- corpuls, a German company, introduced its products at a conference in Fort Worth and is awaiting FDA authorization for U.S. sales.18:39

Related events

Cuong Do leads BioVie as its CEO. BioVie Inc is listed on the NASDAQ exchange and is seeking FDA review for its drug candidate.Aug 6

Coverage

Newest first; wire copies grouped

Aug 13GlobeNewswireErasca Reports Second Quarter 2025 Business Updates and Financial Results Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 m

2 more outlets ran the same wire story

Sep 4yahoo.com
Jul 14insidermonkey.com